Clinical trials: Schizophrenia Spectrum & Other Psychotic Disorders
Schizophrenia, Bipolar Disorder
Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness
The purpose of this study is to evaluate the effectiveness of a mobile real-time cognitive behavioral intervention for serious mental illness (SMI) and to identify the facilitators, barriers, and costs of implementation.
- Trial name
- NCT02035202
- Testing
- CBT2go, Smartphone
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of California, San Diego
Schizophrenia
A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.
Study to compare PK of a new 120mg tablet with two 60mg tablets. This is required because we plan to have only single tablets administered in the later phase clinical trials but we have not had a 120mg strength before.
- Trial name
- NCT00500201
- Testing
- SB- 773812 60 mg, SB- 773812 120 mg
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia Spectrum and Other Psychotic Disorders, Affective Psychoses
SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study
Worries about harm from others (also known as paranoia) are common. Thinking fast or going on gut feelings is natural but can fuel these worries. For some, fast thinking and worries start to get in the way of life.
- Trial name
- NCT06568081
- Testing
- SloMo
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- King's College London
Clozapine, Parkinson's Disease (PD)
Clozapine-related Immunodeficiency in Parkinsons Disease
Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia.
- Conditions
- Clozapine, Parkinson's Disease (PD), Immunodeficiency, Psychosis
- Trial name
- CLOZIDPD (NCT06634641)
- Testing
- blood test
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Schizophrenia
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia.
- Trial name
- Beta (NCT01874756)
- Testing
- LY500307 150mg, LY500307 75mg, LY500307 25mg
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Verbal Memory Training Using Virtual Reality in Schizophrenia
Verbal episodic memory is an independent declarative memory system associated with language and is responsible for storage and conscious recall of previous personal experiences.
- Trial name
- NCT04251195
- Testing
- Cognitive Intervention, Active Control Intervention
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Neuronal Plasticity
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
Aerobic endurance training has shown positive effects on symptoms, cognition, daily functioning, and the structure of the hippocampus in patients with schizophrenia.
- Conditions
- Schizophrenia, Neuronal Plasticity, Exercise
- Trial name
- BrainTrain (NCT05956327)
- Testing
- Aerobic Endurance Training, Flexibility, strengthening and balance training
- Where
- Germany
- Volunteers
- 156 people
- Sponsor
- LMU Klinikum
Schizophrenia
fMRI Cholinergic Mechanisms in Schizophrenia
This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.
- Trial name
- NCT01191827
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 compared with placebo (an inactive substance that is compared with a drug to test if the drug has a real effect in a clinical…
- Trial name
- NCT00728195
- Testing
- JNJ-37822681, Olanzapine
- Where
- 45 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 498 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorders
Implementation of Family Involvement for Persons With Psychotic Disorders.
This study will develop and evaluate a complex intervention to implement guidelines on family involvement for patients with psychotic disorders (F20-29 in International Classification of Diseases ICD-10) in community mental…
- Trial name
- IFIP (NCT03869177)
- Testing
- Implementation support program
- Where
- 15 sites in Norway
- Volunteers
- 460 people
- Sponsor
- University of Oslo
Psychotic Disorders
Epidemiology Study of Psychosis
Purpose Psychotic disorders (including schizophrenia) are complex neurobehaviour disorders influenced by genetic, neurodevelopmental, neurochemical, as well as psychosocial factors.
- Trial name
- NCT01423669
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Schizophrenia, Mania
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
- Trial name
- NCT00102479
- Testing
- Aripiprazole
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Patients Diagnosed With Severe Mental Illness
From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management
The purpose of this study is to determine the benefit and impact on relapse prevention,adherence to treatment and general health indices of participation in psycho-eduational group intervention among psychiatric patients with…
- Trial name
- NCT00192751
- Testing
- Psychoeducational group sessions
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Rambam Health Care Campus
Schizophrenia, Schizoaffective Disorder
Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation
The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) is effective in remediating cognitive deficits while also improving functionality in Veterans with schizophrenia.
- Trial name
- NCT03037983
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Schizoaffective Disorder, Schizophrenia
Genetic Study of Schizophrenia
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
- Trial name
- NCT00001486
- Where
- United States
- Volunteers
- 4,914 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Effect of Quetiapine on Negative Symptoms and Cognition
The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.
- Trial name
- NCT00305422
- Testing
- Quetiapine fumarate, Risperidone
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Smoking Cessation, Schizophrenia
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
- Trial name
- NCT00435370
- Testing
- Tropisetron, Risperidone
- Where
- 2 sites in United States, China
- Volunteers
- 179 people
- Sponsor
- Baylor College of Medicine
Schizophrenia Schizoaffective
Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.
In a randomized controlled design with approximately 26 biweekly sessions over 12 months, the investigators propose to test the effectiveness of an ECHO-based intervention for improving the use of clozapine in people eligible for…
- Trial name
- CHAMPION (NCT04325386)
- Testing
- ECHO Intervention, eTAU
- Where
- United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Brain Imaging in Early Psychosis
This study assesses brain connectivity and function of individuals ages 13-25 at a prodromal or early stage of a psychotic disorder.
- Trial name
- NCT03932188
- Testing
- Mental Health Assessments and Computerized Cognitive Test, MRI scan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.